IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
23 mai 2024 17h00 HE
|
IN8bio, Inc
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
14 mai 2024 10h00 HE
|
IN8bio, Inc
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
13 mai 2024 08h00 HE
|
IN8bio, Inc
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
09 mai 2024 16h00 HE
|
IN8bio, Inc
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
30 avr. 2024 06h05 HE
|
IN8bio, Inc
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
24 avr. 2024 08h00 HE
|
IN8bio, Inc
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
16 avr. 2024 16h05 HE
|
IN8bio, Inc
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
09 avr. 2024 16h30 HE
|
IN8bio, Inc
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
14 mars 2024 16h00 HE
|
IN8bio, Inc
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
05 mars 2024 16h30 HE
|
IN8bio, Inc
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024